share_log

Ascendiant Capital Initiates Coverage On NRX Pharmaceuticals With Buy Rating, Announces Price Target of $4

Ascendiant Capital Initiates Coverage On NRX Pharmaceuticals With Buy Rating, Announces Price Target of $4

Ascendiant Capital以買入評級開始對NRX Pharmicals進行報道,宣佈目標股價爲4美元
Benzinga Real-time News ·  2022/11/09 06:22

Ascendiant Capital analyst Edward Woo initiates coverage on NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announces Price Target of $4.

Ascendiant Capital分析師愛德華·胡以買入評級啓動了對NRX製藥公司(納斯達克股票代碼:NRXP)的報道,並宣佈目標股價爲4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論